Retina/Vitreous News

Aviceda Therapeutics announced the dosing of the first patient in the second part of its phase 2/3 SIGLEC trial investigating AVD-104 to treat geographic atrophy secondary to age-related macular degeneration.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Carl D. Regillo, MD, discusses the impact of supplemental aflibercept on eyes with wet age-related macular degeneration treated with EYP-1901.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, David A. Eichenbaum, MD, discusses data on ABBV-RGX-314 for neovascular age-related macular degeneration.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, discusses 2-year expanded efficacy data on avacincaptad pegol, or ACP, for geographic atrophy.

Toku has obtained CE and UKCA marks for its CLAiR technology to assess cardiovascular disease risk using retinal images, according to a press release.

Individuals with glaucoma, age-related macular degeneration or cataract have a higher risk for both falls and fractures, according to research on a large cohort published in JAMA Ophthalmology.

Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Roger A. Goldberg, MD, MBA, discusses 3-year data investigating pegcetacoplan for the treatment of geographic atrophy.

WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Roger A. Goldberg, MD, MBA, discusses a post hoc analysis of the PHOTON trial investigating aflibercept 8 mg for the treatment of diabetic macular edema.

Kiora Pharmaceuticals has entered into a strategic agreement that grants Théa Open Innovation development and commercialization rights to KIO-301 for the treatment of degenerative retinal diseases.